Skip to main content
All lobbying filings

STANTON PARK GROUP

Lobbying for BRAEBURN PHARMACEUTICALS, INC. · pharmaceutical company

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

 Lobbying activity 2
Health Issues

Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; Patient access to practitioner-administered therapies

Medicare/Medicaid

Pilot programs related to Medicaid pricing

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem